Abstract | BACKGROUND: Sulfonylureas (SUs) have been used for many years as first-line therapy for patients with type 2 diabetes mellitus whose blood glucose levels have not been effectively controlled by diet and exercise alone. Glimepiride is a once-daily SU that was introduced in 1995. Since then, a considerable body of evidence has been amassed regarding its use in type 2 diabetes. OBJECTIVE: METHODS: Relevant articles were identified through a search of MEDLINE for English-language studies published from 1990 to 2002. The search terms used were glimepiride, sulfonylureas, and type 2 diabetes mellitus. The manufacturer of glimepiride provided additional information. RESULTS: CONCLUSION:
|
Authors | Massimo Massi-Benedetti |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 25
Issue 3
Pg. 799-816
(Mar 2003)
ISSN: 0149-2918 [Print] United States |
PMID | 12852703
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Sulfonylurea Compounds
- glimepiride
|
Topics |
- Blood Glucose
(drug effects)
- Body Weight
(drug effects)
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2
(drug therapy)
- Dose-Response Relationship, Drug
- Global Health
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Sulfonylurea Compounds
(therapeutic use)
- Treatment Outcome
|